Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.40) per share. This is a 900 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $3.10 million which beat the analyst consensus estimate of $1.36 million by 127.57 percent. This is a 516.53 percent increase over sales of $502.00 thousand the same period last year.
Credit Suisse Maintains Outperform on Booking Holdings, Raises Price Target to $2985
Credit Suisse analyst Stephen Ju maintains Booking Holdings (NASDAQ:BKNG) with a Outperform and raises the price target from $2850 to $2985.
